Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection
To provide early access to tipranavir and evaluate the safety and tolerance of tipranavir combined with low dose of ritonavir in patients with progressive, HIV-1 disease who have failed or are intolerant to currently approved treatments for HIV infection, who are unable to participate in another tipranavir controlled clinical trial and have an urgent need for anti-HIV treatment.
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||An Open Label Safety Study to Evaluate the Safety of Tipranavir Plus Ritonavir When Used in Combination With Other Agents for the Treatment of Patients With HIV Infection Who Have Failed and/or Are Intolerant to Combination Antiretroviral Therapy and Have Limited Treatment Options|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00062660
|Contact: Boehringer Ingelheim Call Centeremail@example.com|
Show 146 Study Locations
|Study Chair:||Boehringer Ingelheim||Boehringer Ingelheim|